To reach the poor: results from the ISNAR-IFPRI Next Harvest study on genetically modified crops, public research, and policy implications

"Local farming communities throughout the world face productivity constraints, environmental concerns, and diverse nutritional needs. Developing countries address these challenges in a number of ways. One way is public research that produces genetically modified (GM) crops and recognize biotechnology as a part of the solution. To reach these communities, GM crops, after receiving biosafety agreement, must be approved for evaluation under local conditions. However, gaps between approvals in the developed and developing world grow larger, as the process of advancing GM crops in developing countries becomes increasingly difficult. In several countries, only insect resistant cotton has successfully moved from small, confined experimental trials to larger, open trials and to farms. By far, most GM crop approvals have been for commercial products that perform well under tropical conditions. However, complete information on public GM crop research in developing countries has not been assessed. “Will policies and research institutions in the developing world stimulate the safe use of publicly funded GM food crops?” The relatively few GM crops approved from public research, coupled with growing regulatory, biosafety capacity, trade, and political concerns, argue to the contrary. To tackle this issue, we identified and analyzed public research pipelines for GM crops among 16 developing countries and transition economies. Respondents reported 209 genetic transformation events for 46 different crops at the time when the survey was conducted. The pipelines demonstrate scientific progress among publicly funded crop research institutes in participating countries. Information and findings are presented for GM crops nearing final stages of selection. Additional details are provided for the types of genes and traits used, the breadth of genetic resources documented, implications for regulation, and the type of research partnerships employed. Regulations, GM crop approvals, choice of transgene, and policy implications are discussed as they affect this research. Based on these findings, recommendations are presented that would help sustain and increase efficiency of publicly supported research while meeting biosafety requirements. To do so, the study examines results concerning investments and choices made in research, capacity, and policy development for biotechnology. These indicate the risk and potential for GM technologies in developing countries. Policy makers, those funding biotechnology, and other stakeholders can use this information to prioritize investments, consider product advancement, and assess relative magnitude of potential risks, and benefits." Authors' Abstract

Transgenic Crops, Biotechnology and Ownership Rights: What Scientists Need to Know

Ownership of intellectual and tangible property (IP/TP) rights in agricultural biotechnology (ag‐biotech) and transgenic plants has become critically important. For scientists in all institutions, whether industrialized or developing country, public or private sector, an understanding of IP/TP rights is fundamental in both research and development. Transgenic plants and ag‐biotech products embody numerous components and processes, each of which may have IP/TP rights attached. To identify these rights, a transgenic plant or ag‐biotech product must be dissected into its essential components and processes, with each ‘piece’ analysed under the IP/TP ‘microscope’. This product deconstruction is an integral step in product clearance (PC) analysis leading to freedom to operate (FTO). To facilitate a PC analysis, the following points are important: (1) knowing what one has and where it\u27s from, (2) organizing material transfer agreements and licences, (3) researching scientific and patent databases and relevant literature, (4) instituting a laboratory notebook policy, (5) keeping track of ownership of germplasm and plant genetic resources, and (6) promoting ongoing IP/TP management, awareness and training. However, a FTO opinion does not solve the IP/TP issues of releasing a transgenic plant or ag‐biotech product; rather, it is a management tool for assessing the risks of litigation. When transferring transgenic plants or ag‐biotech to developing nations, scientists from industrialized countries have the heightened responsibility of verifying that IP/TP issues are fully addressed and documented. Successful technology transfer goes beyond research, development and licensing; it is an holistic package leading to long‐term partnerships in international development. Managing IP/TP requires capacity‐building in scientists and technology transfer offices, in both industrialized and developing countries

TO REACH THE POOR: RESULTS FROM THE ISNAR-IFPRI NEXT HARVEST STUDY ON GENETICALLY MODIFIED CROPS, PUBLIC RESEARCH, AND POLICY IMPLICATIONS

Local farming communities throughout the world face productivity constraints, environmental concerns, and diverse nutritional needs. Developing countries address these challenges in a number of ways. One way is public research that produces genetically modified (GM) crops and recognize biotechnology as a part of the solution. To reach these communities, GM crops, after receiving biosafety agreement, must be approved for evaluation under local conditions. However, gaps between approvals in the developed and developing world grow larger, as the process of advancing GM crops in developing countries becomes increasingly difficult. In several countries, only insect resistant cotton has successfully moved from small, confined experimental trials to larger, open trials and to farms. By far, most GM crop approvals have been for commercial products that perform well under tropical conditions. However, complete information on public GM crop research in developing countries has not been assessed. Will policies and research institutions in the developing world stimulate the safe use of publicly funded GM food crops? The relatively few GM crops approved from public research, coupled with growing regulatory, biosafety capacity, trade, and political concerns, argue to the contrary. To tackle this issue, we identified and analyzed public research pipelines for GM crops among 16 developing countries and transition economies. Respondents reported 209 genetic transformation events1 for 46 different crops at the time when the survey was conducted. The pipelines demonstrate scientific progress among publicly funded crop research institutes in participating countries. Information and findings are presented for GM crops nearing final stages of selection. Additional details are provided for the types of genes and traits used, the breadth of genetic resources documented, implications for regulation, and the type of research partnerships employed. Regulations, GM crop approvals, choice of transgene, and policy implications are discussed as they affect this research. Based on these findings, recommendations are presented that would help sustain and increase efficiency of publicly supported research while meeting biosafety requirements. To do so, the study examines results concerning investments and choices made in research, capacity, and policy development for biotechnology. These indicate the risk and potential for GM technologies in developing countries. Policy makers, those funding biotechnology, and other stakeholders can use this information to prioritize investments, consider product advancement, and assess relative magnitude of potential risks, and benefits